China Kadoorie Biobank

China Kadoorie Biobank
Name	China Kadoorie Biobank
Established	2004–2008
Location	China
Type	Prospective cohort study
Participants	~512,000 adults
Founders	Oxford University, Peking University, University of Oxford, Kadoorie Charitable Foundation

China Kadoorie Biobank

The China Kadoorie Biobank is a large prospective cohort study established to investigate determinants of chronic disease in Chinese adults. It links large-scale epidemiological data with genetic, clinical, and environmental information to support research similar to that conducted by UK Biobank, Framingham Heart Study, Whitehall Study, Nurses' Health Study, and Million Veteran Program. Funders and collaborators include institutions such as University of Oxford, Peking University, Kadoorie Charitable Foundation, Wellcome Trust, Medical Research Council (United Kingdom), and National Natural Science Foundation of China.

Background and Objectives

The project was launched against the backdrop of rapid demographic and epidemiological transitions exemplified by research from World Health Organization, China CDC, Harvard T.H. Chan School of Public Health, Imperial College London, and Johns Hopkins Bloomberg School of Public Health. Primary objectives included quantifying associations between lifestyle exposures and major outcomes similar to work from Global Burden of Disease Study, Interheart Study, Prospective Studies Collaboration, and PURE study. The initiative sought to complement molecular epidemiology programs such as International HapMap Project, 1000 Genomes Project, and consortia like CARDIoGRAMplusC4D and GIANT Consortium.

Cohort Design and Recruitment

Recruitment mirrored strategies used in established cohorts including EPIC study, Rotterdam Study, and ARIC Study, engaging about half a million adults aged 30–79 across 10 diverse regions comparable to sites in Beijing, Shanghai, Guangxi, Sichuan, Henan, Hunan, and Liaoning. Fieldwork teams coordinated with local centers such as Peking University Health Science Center, Fudan University, Sun Yat-sen University, and regional public health institutions like Shanghai CDC and Guangzhou CDC. Recruitment waves drew on community registers and outreach practices similar to Framingham Heart Study recruitment campaigns and leveraged mobile health platforms used by Tencent and Baidu for participant communication.

Data Collection and Baseline Measurements

Baseline visits collected questionnaire data, anthropometry, blood samples, and blood pressure measured with protocols akin to WHO STEPS standards and laboratory assays comparable to those run by NHS Blood and Transplant and Centers for Disease Control and Prevention (United States). Biological aliquots supported genomic assays in collaboration with genomics groups at Wellcome Sanger Institute, Broad Institute, and BGI. Detailed exposure assessment included tobacco use patterns paralleling work on China Smoking Survey, dietary assessment methods resonant with Food Frequency Questionnaire adaptations used by Harvard School of Public Health, and activity measures comparable to accelerometry studies at Oxford Centre for Diabetes, Endocrinology and Metabolism.

Follow-up, Linkage and Outcome Ascertainment

Follow-up integrated passive and active approaches using health insurance claims systems such as China Health Insurance Research Association databases, mortality linkage with National Death Registry (China), and hospital records akin to linkages in Scandinavian registries and UK NHS Digital. Outcomes ascertained include stroke phenotypes evaluated against WHO criteria, myocardial infarction validated using ICD codes similar to ICD-10 applications used by American Heart Association, cancer diagnoses cross-referenced with provincial cancer registries like Shanghai Cancer Registry, and cause-specific mortality harmonized with standards from Global Burden of Disease Study collaborators.

Governance, Ethics and Data Access

Governance structures reflect models from European Prospective Investigation into Cancer and Nutrition and UK Biobank with oversight by institutional review boards at Oxford University Ethics Committee and Chinese ethics committees at Peking University Ethics Committee. Consent and ethical frameworks drew on guidance from Declaration of Helsinki, CIOMS, and national regulations administered by National Health Commission (China). Data access policies permit collaborative applications akin to consortia procedures used by International Stroke Genetics Consortium, Global Lipids Genetics Consortium, and CHARGE Consortium, with data sharing agreements negotiated among parties including University of Oxford, Peking University, Wellcome Trust, and international research centers.

Key Findings and Publications

Major publications have addressed blood pressure relationships akin to findings from the Prospective Studies Collaboration, smoking risks comparable to analyses by Surgeon General of the United States, and diabetes epidemiology paralleling studies at Harvard Medical School. Results have contributed to consortia such as CHARGE Consortium, MEGASTROKE, CARDIoGRAM, Global Lipids Genetics Consortium, and GIANT Consortium. High-impact papers in journals comparable to The Lancet, Nature Genetics, BMJ, JAMA, and Circulation have reported on cardiovascular risk factors, cancer incidence patterns, genetic associations, and air pollution effects similar to multi-cohort meta-analyses by Global Burden of Disease Study teams. Ongoing work integrates polygenic risk score research linked to methodologies from International HapMap Project and statistical approaches from PLINK and GCTA toolkits.

Category:Cohort studies